Oxcarbazepine Tablet, Film Coated
Product Images NDC 55154-4323

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 55154-4323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (4ebcb0e5 1c93 4b3f 8749 6835c56afce5 00)

OXCARBAZEPINE tablets, USP 300 mg, film coated tablet, in a package containing 10 tablets. Label includes storage instructions, dosing references, and warnings. Manufactured by LGM Pharma Solutions, LLC, and distributed by Cardinal Health 107, LLC and other entities. The label features NDC 55154-4320-0 and highlights that the product is prescription only with a pharmacist dispensing guide.*

FDA Label Image

Bag Label (4ebcb0e5 1c93 4b3f 8749 6835c56afce5 01)

Label for Oxcarbazepine Tablets, USP 150 mg, film coated oral tablets in a package of 10 tablets. The label includes storage instructions, dosage guidance reference, color additive information, and warnings. Manufacturer is LGM Pharma Solutions, LLC, with distribution and packaging by Major Pharmaceuticals and Cardinal Health.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, showing its molecular framework with two benzene rings fused to a central ring containing a ketone and an amide group.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier plot comparing exit rates over time on trial from Day 2 to Day 11 (in days) for two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The vertical axis represents the exit rate (0 to 1). The graph includes a log-rank test p-value of 0.0001, indicating statistical comparison between groups.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve showing seizure rate over days from first dose to first seizure. The graph compares two treatment groups: Oxcarbazepine and Placebo, with seizure rate on the y-axis and days on the x-axis. It includes a log-rank test p-value of 0.046 indicating statistical comparison.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier survival curve chart showing exit rate over time to exit in days for two treatment groups labeled HIGH and LOW. The time to exit ranges from 0 to 130 days, and the exit rate ranges from 0.0 to 1.0. The HIGH group is represented by a solid line, and the LOW group by a dotted line. The chart includes a log-rank test p-value of 0.0001.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier curve chart depicting exit rates over time in days for two treatment groups labeled HIGH and LOW. The y-axis shows exit rate from 0 to 1.0, and the x-axis shows time to exit in days from 0 to 130. The LOW group has a higher exit rate over time compared to the HIGH group. The chart includes a log-rank test p-value of 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.